Researchers testing vaccine to help people quit smoking

May 21, 2010

In a unique twist to a decades-old health crisis, Michigan State University researchers are testing a new vaccine to help people quit smoking and avoid relapses.

Using a - as opposed to patches or gums, which attempt to wean people off nicotine - is a novel approach to the addiction that results in more than $192 billion in health care costs each year, according to federal estimates.

The vaccine, called NicVAX, is being developed and manufactured by Nabi Biopharmaceuticals of Rockville, Md. It will be tested at 25 sites nationwide.

Jonathan Henry, an associate professor with MSU's Department of Psychiatry and the Clinical and Translational Sciences Institute, is leading the clinical trial at MSU.

"Using a vaccine to treat is one of the most unique approaches to battling addiction," Henry said. "We are very hopeful this strategy will help smokers kick the habit."

The vaccine works by preventing a smoker from "feeling good" while smoking. When nicotine enters the bloodstream, it quickly crosses the blood-brain barrier, triggering the release of stimulants such as that provide the smoker with a positive sensation, eventually leading to addiction.

NicVAX stimulates the immune system to produce antibodies that bind with and prevent from crossing the blood-brain barrier, essentially preventing the highly-addictive pleasure sensation experienced by smokers.

Vaccine developers hope that prevention helps people quit , and because the antibodies remain in the bloodstream for several months, the vaccine could be effective in preventing relapse. With current smoking-cessation therapies, relapse rates can be as high as 90 percent in the first year after a smoker quits.

During the clinical trial, participants will receive the vaccine several times throughout a 12-month period. Results from the placebo-controlled study are expected to be available in early 2012. If the clinical trial proves successful, Nabi Biopharmaceuticals will Food and Drug Administration approval shortly thereafter.

At MSU, about 50 people will take part in the clinical trial, which nationwide will test 1,000 participants. Henry and his team of researchers, from the departments of Psychiatry and Family Medicine and the Clinical and Translational Sciences Institute, are seeking subjects for the trial.

Participants must be smokers ages 18 to 65 who smoke at least 10 cigarettes per day and are motivated to quit.

Explore further: Study identifies challenges faced by NYU nurses after Hurricane Sandy

Related Stories

Nicotine vaccine under development

Jun 26, 2006

U.S. scientists say new medications might soon be available to help people stop smoking by attacking nicotine addition in the brain.

Naltrexone can help heavy social drinkers quit smoking

Mar 19, 2009

Naltrexone, an opioid antagonist approved in 1994 by the U.S. Food and Drug Administration for alcohol-dependence (AD) treatment, can reduce relapse rates among AD patients. Research on naltrexone's effectiveness on nicotine ...

Recommended for you

With kids in school, parents can work out

18 hours ago

(HealthDay)—Back-to-school time provides an opportunity for parents to develop an exercise plan that fits into the family schedules, an expert suggests.

Obama offers new accommodations on birth control

22 hours ago

The Obama administration will offer a new accommodation to religious nonprofits that object to covering birth control for their employees. The measure allows those groups to notify the government, rather than their insurance ...

Use a rule of thumb to control how much you drink

23 hours ago

Sticking to a general rule of pouring just a half glass of wine limits the likelihood of overconsumption, even for men with a higher body mass index. That's the finding of a new Iowa State and Cornell University ...

User comments : 0